Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

NCT07694427 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Mocertatug rezetecan
DRUG: Bevacizumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]